Port Catheter Needle Insert: A Virtual Reality Application

July 24, 2023 updated by: Derya ÇINAR, Izmir Bakircay University

Effect of Virtual Reality Application on Pain, Anxiety, and Vital Findings Due to Port Catheter Needle Insert Randomized Controlled Study

The study was randomized controlled to examine the effect of virtual reality (VR) application on pain, anxiety, and vital signs associated with port catheter needle insertion. This study was conducted as a parallel-group, randomized controlled intervention study. The study was conducted with 84 cancer patients who came to Bursa Uludağ University outpatient chemotherapy unit for treatment between December 2022 and May 2023 and met the inclusion criteria. Patients undergoing port catheterization were randomly assigned to the intervention (n=42) and control (n=42) groups. During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses. In the control group, no intervention was made except the routine application.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The purpose and rationale of the study were explained to the patients who met the inclusion criteria. Written informed consent was obtained from the patients who agreed to participate in the study. Patients were assigned to the intervention and control groups by simple randomization. The data of the study were collected simultaneously from both groups.

Standard care was applied to both groups during the port needle intervention procedure. Patients assigned to the intervention group were given standard care and VR application. The State Anxiety Scale was administered to the patients in both groups before the port catheter insertion procedure. Blood pressure, heart rate, respiratory rate, and oxygen saturation were measured and vital signs were recorded in the follow-up chart. The patients in the intervention group were informed by the researcher about the use of VR glasses and viewing the images. The contents of the VR images were shown to the patients on the smartphone and one of the images was presented to their preferences. Afterward, the patient was seated in the chair where he would receive chemotherapy, and VR glasses and headgear were put on. From the moment the position was given, the images preferred by the patients were applied to the VR application, which lasted for an average of 3 minutes, through VR glasses throughout the procedure. After the procedure was completed, the VR glasses were removed. Then, the State Anxiety Inventory, one of the data collection tools, was administered to the patients again. Visual Analogue Scale was used to determine the pain level of the patients due to the needle insertion procedure for the port catheter. After the procedure was completed, the patient's blood pressure, heart rate, respiratory rate, and oxygen saturation were measured again, and vital signs were recorded in the follow-up chart.

Study Type

Interventional

Enrollment (Actual)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • İzmir, Turkey, 35665
        • İzmir Bakırçay University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Receiving active chemotherapy
  • Those with a diagnosis of stage I-II and III cancer
  • Those who volunteered to participate in the research
  • With the implantable venous port catheter
  • Those who will use virtual reality glasses for the first time

Exclusion Criteria:

  • With metastases
  • Receiving anxiolytic drug therapy
  • Receiving antidepressant medication
  • Communication, hearing, and vision problems
  • Having any psychiatric disorder
  • Using any analgesic drug at least 8 hours before
  • Those with migraine, vertigo, active nausea-vomiting, headache, dizziness

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Virtual reality application group
During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.

During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.

With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over.

No Intervention: Control
In the control group, no intervention was made other than the routine application.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vital signs chart-I
Time Frame: up to 24 hours
It is applied to record patients by measuring systolic pressure (mmHg) at pre-intervention and post-intervention.
up to 24 hours
Vital signs chart-II
Time Frame: up to 24 hours
It is applied to record patients by measuring diastolic pressure (mmHg) at pre-intervention and post-intervention.
up to 24 hours
Vital signs chart-III
Time Frame: up to 24 hours
It is applied to record patients by measuring heart rate/ minute at pre-intervention and post-intervention.
up to 24 hours
Vital signs chart-IV
Time Frame: up to 24 hours
It is applied to record patients by measuring respiratory rate/ minute at pre-intervention and post-intervention.
up to 24 hours
Vital signs chart-V
Time Frame: up to 24 hours
It is applied to record patients by measuring oxygen saturation (%) at pre-intervention and post-intervention.
up to 24 hours
The State Anxiety Inventory
Time Frame: up to 24 hours
It is a test developed by Spielberger et al. that measures state and trait anxiety levels. Its validity and reliability in Turkey was done by Öner and Le Compte. The scale consists of two parts, the 'state anxiety scale', which is created with the aim of determining the instantaneous feelings, and the 20-item 'trait anxiety scale', which was created to determine the feelings in general. It is a four degree scale ranging from 'Nothing' to 'All'. Scores range from 20 (low anxiety) to 80 (high anxiety).
up to 24 hours
Visual Analog Scale
Time Frame: up to 24 hours

VAS is a scale developed by Price et al. and measures the severity of pain in the patient. VAS is a 10 cm long vertical or horizontal scale with two different names (0=no pain, 10=most severe pain). An increase in the score obtained from the scale in the evaluation indicates an increase in pain.

It is applied to determine the severity of pain in patients at immediately after the intervention.

up to 24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Derya ÇINAR, Assoc. prof., Izmir Bakircay University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2022

Primary Completion (Actual)

May 15, 2023

Study Completion (Actual)

June 10, 2023

Study Registration Dates

First Submitted

June 12, 2023

First Submitted That Met QC Criteria

July 10, 2023

First Posted (Actual)

July 18, 2023

Study Record Updates

Last Update Posted (Actual)

July 25, 2023

Last Update Submitted That Met QC Criteria

July 24, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • Bakircay

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Catheter Complications

Clinical Trials on Virtual reality application

Subscribe